Immuneering Historical Income Statement

IMRX Stock

USD 2.08 0.02 0.95%

Historical analysis of Immuneering Corp income statement accounts such as Depreciation And Amortization of 369.7 K or Interest Expense of 1.2 M can show how well Immuneering Corp performed in making a profits. Evaluating Immuneering Corp income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immuneering Corp's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Immuneering Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immuneering Corp is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immuneering Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

About Immuneering Income Statement Analysis

Immuneering Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immuneering Corp shareholders. The income statement also shows Immuneering investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Immuneering Corp Income Statement Chart

At this time, Immuneering Corp's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 3.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 10.2 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Ebit Research Development Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Immuneering Corp generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Immuneering Corp. It is also known as Immuneering Corp overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Immuneering Corp's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immuneering Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immuneering Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.At this time, Immuneering Corp's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 3.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 10.2 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	34.8M	51.9M	58.4M	37.5M
Cost Of Revenue	1.2M	158.1K	764.1K	732.6K

Total Operating Expenses Cost Of Revenue

Immuneering Corp income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Tax Provision	Non Operating Income Net Other	Selling And Marketing Expenses
Net Interest Income		0.95	0.86	0.84	0.86	-0.88	-0.88	0.9	-0.96	-0.94	-0.96	0.9	-0.96	-0.69	0.9	0.94	-0.94	0.99	-0.95	-0.52	0.9	0.93	-0.85
Interest Income	0.95		0.67	0.91	0.78	-0.92	-0.98	0.77	-0.86	-0.83	-0.86	0.76	-0.87	-0.62	0.77	0.91	-0.84	0.98	-0.85	-0.3	0.89	0.93	-0.93
Depreciation And Amortization	0.86	0.67		0.63	0.88	-0.71	-0.58	0.94	-0.93	-0.94	-0.93	0.95	-0.93	-0.79	0.94	0.85	-0.94	0.81	-0.94	-0.86	0.81	0.79	-0.52
Interest Expense	0.84	0.91	0.63		0.84	-0.99	-0.96	0.77	-0.84	-0.83	-0.84	0.74	-0.85	-0.83	0.77	0.94	-0.83	0.86	-0.84	-0.46	0.96	0.97	-0.79
Selling General Administrative	0.86	0.78	0.88	0.84		-0.89	-0.78	0.98	-0.96	-0.96	-0.96	0.97	-0.96	-0.88	0.98	0.93	-0.96	0.84	-0.96	-0.76	0.92	0.9	-0.54
Total Revenue	-0.88	-0.92	-0.71	-0.99	-0.89		0.96	-0.83	0.89	0.88	0.89	-0.81	0.9	0.86	-0.83	-0.97	0.88	-0.9	0.89	0.53	-0.99	-0.99	0.78
Gross Profit	-0.88	-0.98	-0.58	-0.96	-0.78	0.96		-0.73	0.82	0.79	0.82	-0.71	0.82	0.67	-0.73	-0.91	0.8	-0.92	0.8	0.28	-0.91	-0.94	0.88
Other Operating Expenses	0.9	0.77	0.94	0.77	0.98	-0.83	-0.73		-0.98	-0.98	-0.98	1.0	-0.97	-0.83	1.0	0.92	-0.98	0.86	-0.98	-0.78	0.88	0.87	-0.55
Operating Income	-0.96	-0.86	-0.93	-0.84	-0.96	0.89	0.82	-0.98		1.0	1.0	-0.97	1.0	0.83	-0.97	-0.97	1.0	-0.93	1.0	0.72	-0.93	-0.93	0.71
Net Income From Continuing Ops	-0.94	-0.83	-0.94	-0.83	-0.96	0.88	0.79	-0.98	1.0		1.0	-0.98	1.0	0.85	-0.98	-0.96	1.0	-0.91	1.0	0.76	-0.92	-0.92	0.67
Ebit	-0.96	-0.86	-0.93	-0.84	-0.96	0.89	0.82	-0.98	1.0	1.0		-0.97	1.0	0.83	-0.98	-0.97	1.0	-0.93	1.0	0.72	-0.93	-0.93	0.71
Research Development	0.9	0.76	0.95	0.74	0.97	-0.81	-0.71	1.0	-0.97	-0.98	-0.97		-0.97	-0.81	1.0	0.9	-0.98	0.86	-0.98	-0.78	0.87	0.86	-0.55
Ebitda	-0.96	-0.87	-0.93	-0.85	-0.96	0.9	0.82	-0.97	1.0	1.0	1.0	-0.97		0.83	-0.97	-0.97	1.0	-0.93	1.0	0.72	-0.93	-0.93	0.71
Cost Of Revenue	-0.69	-0.62	-0.79	-0.83	-0.88	0.86	0.67	-0.83	0.83	0.85	0.83	-0.81	0.83		-0.83	-0.88	0.84	-0.66	0.84	0.85	-0.9	-0.87	0.43
Total Operating Expenses	0.9	0.77	0.94	0.77	0.98	-0.83	-0.73	1.0	-0.97	-0.98	-0.98	1.0	-0.97	-0.83		0.92	-0.98	0.86	-0.98	-0.78	0.89	0.87	-0.55
Reconciled Depreciation	0.94	0.91	0.85	0.94	0.93	-0.97	-0.91	0.92	-0.97	-0.96	-0.97	0.9	-0.97	-0.88	0.92		-0.96	0.94	-0.96	-0.65	0.99	0.99	-0.77
Income Before Tax	-0.94	-0.84	-0.94	-0.83	-0.96	0.88	0.8	-0.98	1.0	1.0	1.0	-0.98	1.0	0.84	-0.98	-0.96		-0.92	1.0	0.75	-0.93	-0.92	0.69
Total Other Income Expense Net	0.99	0.98	0.81	0.86	0.84	-0.9	-0.92	0.86	-0.93	-0.91	-0.93	0.86	-0.93	-0.66	0.86	0.94	-0.92		-0.92	-0.45	0.9	0.93	-0.89
Net Income	-0.95	-0.85	-0.94	-0.84	-0.96	0.89	0.8	-0.98	1.0	1.0	1.0	-0.98	1.0	0.84	-0.98	-0.96	1.0	-0.92		0.74	-0.93	-0.93	0.7
Income Tax Expense	-0.52	-0.3	-0.86	-0.46	-0.76	0.53	0.28	-0.78	0.72	0.76	0.72	-0.78	0.72	0.85	-0.78	-0.65	0.75	-0.45	0.74		-0.64	-0.59	0.11
Tax Provision	0.9	0.89	0.81	0.96	0.92	-0.99	-0.91	0.88	-0.93	-0.92	-0.93	0.87	-0.93	-0.9	0.89	0.99	-0.93	0.9	-0.93	-0.64		1.0	-0.74
Non Operating Income Net Other	0.93	0.93	0.79	0.97	0.9	-0.99	-0.94	0.87	-0.93	-0.92	-0.93	0.86	-0.93	-0.87	0.87	0.99	-0.92	0.93	-0.93	-0.59	1.0		-0.79
Selling And Marketing Expenses	-0.85	-0.93	-0.52	-0.79	-0.54	0.78	0.88	-0.55	0.71	0.67	0.71	-0.55	0.71	0.43	-0.55	-0.77	0.69	-0.89	0.7	0.11	-0.74	-0.79

Click cells to compare fundamentals

Immuneering Corp Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immuneering Historical Income Statement

About Immuneering Income Statement Analysis

Immuneering Corp Income Statement Chart

Total Revenue

Other Operating Expenses

Total Operating Expenses

Immuneering Corp income statement Correlations

Immuneering Corp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Immuneering Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Non Operating Income Net Other	- 0.99	Total Revenue
Tax Provision	- 0.99	Total Revenue
Total Revenue	- 0.99	Interest Expense
Net Income	- 0.98	Total Operating Expenses
Income Before Tax	- 0.98	Total Operating Expenses
Net Income	- 0.98	Research Development